TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00490139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule inhibitor
Study: NCT01882439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tablets, 5 mg BID x 6 months
Study: NCT00490139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule inhibitor

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Antibody
Study: NCT04608162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF)
Description: PEMF was administered to the whole body using a 1.8×0.6m mat
Study: NCT01882439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tablets, 10 mg BID x 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, to match tofacitinib 5 mg BID x 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: tablets, 5 mg BID x 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, to match tofacitinib 10 mg BID x 3 months
Study: NCT04608162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF)
Description: PEMF was administered to the whole body using a 1.8×0.6m mat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Exercise program to facilitate bone health
Study: NCT01908257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg
Study: NCT04608162

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: Exercise program to facilitate bone health

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PEMF
Description: Patients received placebo PEMF
Study: NCT02437604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Fp MDPI
Description: Fp MDPI 200 mcg, 1 inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: FS MDPI
Description: FS MDPI 200/12.5 mcg, 1 inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C Flovent
Description: FLOVENT DISKUS 250 mcg, 2 inhalations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment D: Advair
Description: ADVAIR DISKUS 500/50 mcg, 1 inhalation
Study: NCT03381313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioned word repetition training
Description: In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
Study: NCT03689244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets without active compound
Study: NCT04464824

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03303118

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia
Description: No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
Study: NCT03400631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 0
Description: Dextrose injection at time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspiration 0
Description: Aspiration only at time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 1
Description: Dextrose injection at week 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspiration 1
Description: Aspiration only at week 1
Study: NCT02332733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV003
Description: 10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TV003
Description: To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
Study: NCT03263780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
Study: NCT03132025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Capecitabine
Description: Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Study: NCT02285530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery group
Description: Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery group
Description: Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.

Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study: NCT01014455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informing surgical patients about CO monitoring
Description: A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a brief intervention recommending preoperative abstinence from smoking
Description: a brief intervention that recommends fasting but does not mention that CO will be checked
Study: NCT03510325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Commonly used oral antipsychotics intervention therapy.
Study: NCT01908257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg + ranitidine 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg + ranitidine 150 mg
Study: NCT01061242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep promoting interventions
Description: MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
Study: NCT00312091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine, nevirapine, and stavudine fixed-dose tablet
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine, nevirapine, and stavudine fixed-dose tablet
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine, nevirapine, and stavudine fixed-dose tablet
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine, nevirapine, and stavudine fixed-dose tablet
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study: NCT03961607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study: NCT03090854

Intervention type: DIAGNOSTIC_TEST
Intervention: ADASCog
Description: Neuropsychological test
Study: NCT01053689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride tablets 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride tablets 1 mg
Study: NCT04497077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry
Description: Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
Study: NCT01882439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: tablets, 10 mg BID x 3 months
Study: NCT03068182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm crank
Description: Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT04269629

Intervention type: DRUG
Intervention: Insect Venom
Description: Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
Study: NCT03710460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.
Study: NCT03004339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 0.15%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOR007 Ointment Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex® Ointment
Study: NCT02488954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics in the form of cheese portion
Study: NCT04497077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry
Description: Either tart cherry juice or freeze dried powdered tart cherry in capsule was given

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry
Description: Either tart cherry juice or freeze dried powdered tart cherry in capsule was given

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry
Description: Either tart cherry juice or freeze dried powdered tart cherry in capsule was given

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: either cornstarch capsule or kool-aid
Study: NCT04218734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108
Description: DBPR108: 100 mg, once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin hydrochloride
Description: metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
Study: NCT03710460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus Metformin XR
Description: 10/1000 mg, one per day before breakfast during 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: 1000 mg, one per day before breakfast during 12 weeks.
Study: NCT03510325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Commonly used oral antipsychotics intervention therapy.
Study: NCT04063059

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIDE counseling intervention
Description: Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
Study: NCT00642343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of motor proficiency skills.
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of motor proficiency
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
Study: NCT01051869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple decompression
Description: Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior subcutaneous transposition
Description: In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
Study: NCT03200574

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 4D Cardiac CT Scan
Description: 4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: LivaNova Bioprothetic Aortic Valve Implant
Description: Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
Study: NCT04266496

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
Study: NCT00642343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of motor proficiency
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of motor proficiency.
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
Study: NCT04354870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
Study: NCT04218734

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placepo
Description: placebo:100 mg, once daily for 24 weeks.
Study: NCT02307773

Intervention type: DRUG
Intervention: Case Group
Description: Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
Study: NCT02109653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: Oral LGX818 300mg daily
Study: NCT02214537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MACS
Study: NCT02333656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New OA model
Description: The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist.
Study: NCT01117571

Intervention type: DEVICE
Intervention: iUni® Unicompartmental Knee Resurfacing Device
Description: The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
Study: NCT04400422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipano formula
Description: Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
Study: NCT02614274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical joint health formulation
Description: A Proprietary Blend
Study: NCT01545518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG 2 mg/kg in two divided doses with placebo crossover
Study: NCT01117649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 10%
Description: HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HES 6%
Description: HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: balanced electrolyte solution
Description: plasma adapted Ringer's solution
Study: NCT04497077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: either cornstarch capsule or kool-aid
Study: NCT04577937

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LAM patients underwent PSG
Description: Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
Study: NCT03796780

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extra-Virgin Olive Oil
Description: Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Refined Olive Oil
Description: Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
Study: NCT00959218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: oral solution, daily dose up to 15 mg, treatment up to 2.5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution